Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Refocus, Optimize, Externalize: Takeda Overhauls Global R&D

Executive Summary

As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.

Advertisement

Related Content

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline
Takeda Extends PRA Alliance To Japan With New JV
Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?
New Bridge Venture Aligns With Takeda Externalization Strategy
Will Japan Pharma Fall In Line With R&D Externalization Trends?
Japan Issues Strong Warning Over Brexit
Takeda Chooses PRA To Lead Its Revamped Clinical Development Ops
Takeda Deepens Links As London Touts Life Science Credentials

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel